



(11) **EP 2 668 953 A1**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
04.12.2013 Bulletin 2013/49

(51) Int Cl.:
A61K 31/7004 ^(2006.01) **A61K 31/351** ^(2006.01)
A61P 19/06 ^(2006.01) **A61K 45/06** ^(2006.01)
A61K 31/60 ^(2006.01)

(21) Application number: **13181659.7**

(22) Date of filing: **15.05.2009**

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL
PT RO SE SI SK TR**

(30) Priority: **22.05.2008 US 55352 P**

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
09751249.5 / 2 291 189

(71) Applicant: **Bristol-Myers Squibb Company
Princeton, NJ 08543-4000 (US)**

(72) Inventor: **Leslie, Bruce, Robert
Princeton, NJ New Jersey 08534-4000 (US)**

(74) Representative: **Reitstötter - Kinzebach
Patentanwälte
Sternwartstrasse 4
81679 München (DE)**

Remarks:

This application was filed on 26-08-2013 as a
divisional application to the application mentioned
under INID code 62.

(54) **Pharmaceutical compositions comprising an SGLT2 inhibitor with a supply of carbohydrate
and/or an inhibitor of uric acid synthesis**

(57) Pharmaceutical compositions comprising an
SGLT2 inhibitor with a supply of carbohydrate or an in-
hibitor of uric acid synthesis or a supply of carbohydrate
and an inhibitor of uric acid synthesis are provided in the

instant invention and are provided for use in methods for
treating hyperuricemia.

EP 2 668 953 A1

Description**FIELD OF THE INVENTION**

- 5 **[0001]** The invention relates to methods for treating hyperuricemia, comprising administering an SGLT2 inhibitor alone or in combination with a carbohydrate and/or an agent that inhibits uric acid synthesis, and to compositions thereof.

BACKGROUND OF THE INVENTION

- 10 **[0002]** Hyperuricemia is a condition of high serum total urate levels. In humans and higher primates, uric acid is the final oxidation product of purine catabolism. In most other mammals, however, the enzyme uricase further oxidizes uric acid to allantoin. In human and higher primates, which lack the enzyme uricase, purine metabolites such as xanthine and hypoxanthine are oxidized by xanthine oxidase to uric acid. In human blood, uric acid concentrations between 3.6 mg/dL (~214 μ mol/L) Association. The presence of total urates including uric acid in the serum is important and beneficial
15 because these compounds are potent antioxidants. In humans, about half the antioxidant capacity of plasma comes from total urates including uric acid.

- [0003]** On the other hand, high serum total urate levels, or hyperuricemia, are often associated with several maladies. For example, high serum total urate levels can lead to a type of arthritis in the joints known as gout. Gout is a condition created by a build up of monosodium urate or uric acid crystals on the articular cartilage of joints, tendons and surrounding
20 tissues due to elevated concentrations of total urate levels in the blood stream. The build up of urate or uric acid on these tissues provokes an inflammatory reaction of these tissues. Saturation levels of uric acid in urine may result in one form of kidney stones when the uric acid or urate crystallizes in the kidney. These uric acid stones are radiolucent and so do not appear on an abdominal x-ray. Therefore, their presence must be diagnosed by ultrasound. Some patients with gout eventually develop uric kidney stones.

- 25 **[0004]** Additionally, high serum total urate levels are often associated with the so-called metabolic syndrome, including cardiovascular disease and hypertension. Conventionally, it was believed that high total urate levels are merely innocuous or could even be beneficial because of the antioxidant activity of uric acid. More recently, however, this view has been challenged. Rather, it has been proposed that total urates are a true risk factor for cardiovascular disease and hyper-
30 tension. In a rat animal model, hyperuricemia resulted in lowering endothelial nitric oxide levels, reducing neuronal nitric oxide synthase in the macula densa of the kidney, and stimulating the rennin-angiotensin system. Over time, the rats developed renal microvascular lesions and eventually hypertension. Heinig et al. Cleveland Clinic Journal of Medicine, 2006, 73:1059-1064. Thus, there is evidence that high serum total urate level, or hyperuricemia, is a risk factor for hypertension.

- [0005]** Hyperuricemia is caused either by accelerated generation of total urates and uric acid through purine metabolism
35 or by impaired excretion of total urates in the urine. Consumption of purine-rich diets is one of the causes of hyperuricemia. High levels of fructose in the diet may also cause hyperuricemia. Other dietary causes are ingestion of high protein and fat, and starvation. Starvation results in the body metabolizing its own muscle mass for energy, in the process releasing purines into the bloodstream. Hyperuricemia may lead to renal diseases and may also exacerbate existing renal conditions.

- 40 **[0006]** Conventional chronic, prophylactic treatments of gout or other high uric acid-associated diseases include administering to a patient an uricosuric drug, which augments urinary uric acid excretion, such as probenecid, sulfapyrazone, or benzbromarone; and/or an inhibitor of xanthine oxidase, such as allopurinol, febuxostat, or oxypurinol. A xanthine oxidase inhibitor reduces total urate production in the body. Allopurinol, the most commonly used xanthine oxidase inhibitor, is associated with side-effects in up to 20% of patients. Therefore, there remains a need for additional safe
45 and effective treatments for hyperuricemia.

SUMMARY OF THE INVENTION

- 50 **[0007]** This invention provides methods and reagents for treating hyperuricemia by inhibiting a sodium glucose transporter expressed in the kidney called SGLT2. SGLT2 is a member of a family of proteins that utilizes an electrochemical sodium gradient to transport glucose, against the sodium concentration gradient inside the cells. Different Na⁺/Glucose transporters are found in different tissues: SGLT1 is mainly found in intestinal mucosa in the small intestine and the S3 segment of the proximal tubule of the nephron in the kidney; and SGLT2 is mainly found in the S1 segment of the proximal tubule of the nephron in the kidney. As set forth herein, SGLT2 inhibitors increase urine excretion of glucose.
55 This increase in urinary glucose excretion is beneficial as a treatment for hyperuricemia.

- [0008]** In one aspect, the invention provides methods for treating hyperuricemia in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of an SGLT2 inhibitor. In one embodiment, the SGLT2 inhibitor is dapagliflozin (compound I). In yet another embodiment, the SGLT2 inhibitor compound is dapagliflo-

flozin PGS (compound Ia). In certain embodiments of this aspect, the methods of the invention for treating hyperuricemia in a mammal comprise administering to the mammal in need thereof a pharmaceutical composition comprising a therapeutically effective amount of SGLT2 inhibitor, and optionally at least one pharmaceutically-acceptable carrier, excipient or diluent.

5 **[0009]** In another aspect, the invention provides methods for treating hyperuricemia in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of an SGLT2 inhibitor and a supply of carbohydrate. The carbohydrate can be supplied prior to, after, or concurrently with the SGLT2 inhibitor and, optionally, another anti-hyperuricemic agent.

10 **[0010]** In a further aspect, these methods of the invention comprise administering to the mammal, in addition to a therapeutically effective amount of an SGLT2 inhibitor, an inhibitor of uric acid synthesis, such as a xanthine oxidase inhibitor, where the inhibitor of uric acid synthesis is administered prior to, after, or concurrently with the SGLT2 inhibitor. In a particular embodiment of the invention, the inhibitor of uric acid synthesis is a xanthine oxidase inhibitor.

[0011] In yet another embodiment, the methods of the invention comprises administering to the mammal a therapeutically effective amount of an SGLT2 inhibitor, a supply of carbohydrate, and an inhibitor of uric acid synthesis.

15 **[0012]** In certain embodiments of this aspect, the methods of the invention for treating hyperuricemia in a mammal comprise administering to the mammal in need thereof a pharmaceutical composition comprising a therapeutically effective amount of SGLT2 inhibitor, a supply of carbohydrate or an inhibitor of uric acid synthesis or both a supply of carbohydrate and optionally an inhibitor of uric acid synthesis, and at least one pharmaceutically-acceptable carrier, excipient or diluent.

20 **[0013]** In a further aspect, the invention provides pharmaceutical compositions for treating hyperuricemia comprising an SGLT2 inhibitor and an inhibitor of uric acid synthesis. In one embodiment, the pharmaceutical compositions further comprise at least one pharmaceutically-acceptable carrier, excipient or diluent.

25 **[0014]** In another aspect, the invention provides pharmaceutical compositions for treating hyperuricemia comprising an SGLT2 inhibitor and a source of carbohydrate or an inhibitor of uric acid synthesis or both a source of carbohydrate and an inhibitor of uric acid synthesis. In one embodiment, the pharmaceutical compositions further comprise at least one pharmaceutically-acceptable carrier, excipient or diluent.

30 **[0015]** In yet another aspect, the invention provides methods for treating gout due to hyperuricemia in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of an SGLT2 inhibitor. In one embodiment, the SGLT2 inhibitor is dapagliflozin (compound I). In yet another embodiment, the SGLT2 inhibitor compound is dapagliflozin PGS (compound Ia). In certain embodiments of this aspect, the methods of the invention for treating hyperuricemia in a mammal comprise administering to the mammal in need thereof a pharmaceutical composition comprising a therapeutically effective amount of SGLT2 inhibitor, and optionally at least one pharmaceutically-acceptable carrier, excipient or diluent.

35 **[0016]** In another aspect, the invention provides methods for treating gout in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of an SGLT2 inhibitor and a supply of carbohydrate. The carbohydrate can be supplied prior to, after, or concurrently with the SGLT2 inhibitor. In a further aspect, these methods of the invention comprise administering to the mammal, in addition to a therapeutically effective amount of an SGLT2 inhibitor, an inhibitor of uric acid synthesis where the inhibitor of uric acid synthesis is administered prior to, after, or concurrently with the SGLT2 inhibitor. In a particular embodiment of the invention, the inhibitor of uric acid synthesis is a xanthine oxidase inhibitor. In yet another embodiment, the methods of the invention comprises administering to the mammal a therapeutically effective amount of an SGLT2 inhibitor, a supply of carbohydrate, and an inhibitor of uric acid synthesis. In certain embodiments of this aspect, the methods of the invention for treating gout in a mammal comprise administering to the mammal in need thereof a pharmaceutical composition comprising a therapeutically effective amount of SGLT2 inhibitor, a supply of carbohydrate or an inhibitor of uric acid synthesis or both a supply of carbohydrate and an inhibitor of uric acid synthesis, and at least one pharmaceutically-acceptable carrier, excipient or diluent.

45 **[0017]** In another aspect, the invention provides pharmaceutical compositions for treating hyperuricemia comprising an SGLT2 inhibitor and a source of carbohydrate or an inhibitor of uric acid synthesis or both a source of carbohydrate and an inhibitor of uric acid synthesis. In one embodiment, the pharmaceutical compositions further comprise at least one pharmaceutically-acceptable carrier, excipient or diluent.

50 **[0018]** Specific preferred embodiments of the present invention will become evident from the following more detailed description of certain preferred embodiments and the claims.

BRIEF DESCRIPTION OF THE FIGURES

55 **[0019]** The invention is illustrated by reference to the accompanying drawings described below.

[0020] Figure 1 shows two bar graphs comparing urine glucose excretion in healthy individuals that were treated with GSK 869,682 (top panel) and dapagliflozin PGS (bottom panel).

[0021] Figure 2 shows a graph depicting urine glucose excretion in diabetic subjects treated with different doses of dapagliflozin PGS.

[0022] Figure 3 shows a bar graph depicting urine glucose excretion in diabetic subjects treated with different doses of dapagliflozin PGS.

5

DETAILED DESCRIPTION OF THE INVENTION

[0023] The invention provides methods and reagents directed towards treating hyperuricemia in a mammal in need thereof. In particular, these methods and reagents are capable of facilitating the lowering of serum total urate levels in the animal, and alleviation of the symptoms of gout, hypertension, renal failure, and other hyperuricemia-associated conditions in the mammal.

[0024] In one aspect, the invention provides methods for treating hyperuricemia in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a sodium glucose transporter 2 (SGLT2) inhibitor. In another aspect, the invention provides methods for treating hyperuricemia in a mammal further comprising administering to the mammal at least one additional reagent that facilitates and enhances the effects of the SGLT2 inhibitor on the treatment of hyperuricemia. In certain embodiments, the methods of the invention for treating hyperuricemia further comprise administering to the mammal in need thereof a supply of carbohydrate. In certain embodiments of this aspect, the methods of the invention for treating hyperuricemia in a mammal comprise administering to the mammal in need thereof a pharmaceutical composition comprising a therapeutically effective amount of SGLT2 inhibitor, optionally a supply of carbohydrate, and further optionally at least one pharmaceutically-acceptable carrier, excipient or diluent.

[0025] In certain embodiments, the mammal is a human. In yet other embodiments, the mammal suffers from gout and/or renal failure as a result of high serum uric acid levels. The present invention provides methods for lowering serum total urate and treating gout, renal failure and other hyperuricemia-associated diseases.

[0026] In another aspect, the invention provides methods for treating hyperuricemia in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a sodium glucose transporter 2 (SGLT2) inhibitor and an inhibitor of uric acid synthesis wherein the inhibitor of uric acid synthesis is administered before, after, or concurrently with the SGLT2 inhibitor. In certain embodiments, the invention provides methods for treating hyperuricemia in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a SGLT2 inhibitor, a supply of carbohydrate, and an inhibitor of uric acid synthesis.

[0027] In certain embodiments of this aspect, the methods of the invention for treating hyperuricemia in a mammal comprise administering to the mammal in need thereof a pharmaceutical composition comprising a therapeutically effective amount of SGLT2 inhibitor and a supply of carbohydrate or an inhibitor of uric acid synthesis or both a carbohydrate and an inhibitor of uric acid synthesis, and optionally at least one pharmaceutically-acceptable carrier, excipient or diluent. In one embodiment, the inhibitor of uric acid synthesis is a xanthine oxidase inhibitor.

[0028] In yet another aspect, the invention provides a SGLT2 inhibitor for use in therapy in treating hyperuricemia. In a further aspect, the invention provides the use of a SGLT2 inhibitor in the manufacture of a medicament for treating hyperuricemia. In a further aspect, the invention provides a combination of a SGLT2 inhibitor and a supply of carbohydrate or an inhibitor of uric acid synthesis or a supply of carbohydrate and an inhibitor of uric acid synthesis as a medicament for the treatment of hyperuricemia. In another aspect, the invention provides use of a SGLT2 inhibitor in the manufacture of a medicament for treating hyperuricemia, in which such treatment or prevention comprises a combination with a supply of carbohydrate or an inhibitor of uric acid synthesis or a supply of carbohydrate and an inhibitor of uric acid synthesis, for concurrent or sequential use. In certain embodiments, the supply of carbohydrate and/or the inhibitor of uric acid synthesis is used sequentially, either before or after the treatment with the SGLT2 inhibitor. In certain embodiments, the inhibitor of uric acid synthesis is a xanthine oxidase inhibitor.

[0029] Inhibitors of uric acid synthesis suitable for use in the current invention include, but are not limited to, xanthine oxidase inhibitors. Examples of xanthine oxidase inhibitors include, without limitation, allopurinol, febuxostat and oxy-purinol.

[0030] The term "a supply of carbohydrate," or "a source of carbohydrate" as used herein refers to simple or complex carbohydrate either from the daily intake of carbohydrate in the diet or from a supplement formulated with the SGLT2 inhibitor of the present invention or provided in conjunction with the SGLT2 inhibitor. A source of carbohydrate can be used advantageously with the SGLT2 inhibitor of the present invention to increase urine volume. Non-limiting examples of carbohydrate include monosaccharide such as glucose, disaccharides such as sucrose, and complex oligosaccharides or polysaccharides such as starch. The supply of carbohydrate can be provided to the mammal in need of the hyperuricemia treatment before, after, or concurrent with the SGLT2 inhibitor. The carbohydrate of the current invention can be supplied in the range of about 30 to about 270 g per day, preferably in the range of about 60 to about 180 g per day, and most preferably about 90 g, or close to about one third of the mammal's daily carbohydrate intake, per day. It is within the knowledge of one skilled artisan or physician to determine the suitable amount of carbohydrate to be used in the present invention.

[0031] The methods of this invention can be used to treat hyperuricemia in non-diabetic as well as diabetic patients. In one embodiment, the SGLT2 inhibitors employed in the above-defined methods of the invention will not cause hypoglycemia in a non-diabetic mammal, i.e. a mammal that does not suffer from hyperglycemia. In another embodiment, the SGLT2 inhibitors employed in the above-defined methods of the invention will not cause hypoglycemia in a diabetic mammal. It will be understood by the skilled worker that administered amounts and in vivo concentrations of the SGLT2 inhibitors used according to the methods of the invention can be chosen to have anti-hyperuricemia effects without disturbing the recipient's plasma glucose homeostasis.

[0032] Thus, in carrying out the methods of the invention for treating hyperuricemia, the SGLT2 inhibitor can be administered to a patient in need of such treatment in a dose which can be as high as that used to treat hyperuricemia but less than an amount which could cause hypoglycemia. The daily dose can be lowered as successful treatment of hyperuricemia is achieved. For example, depending upon the patient, and the specific SGLT2 inhibitor employed, the SGLT2 inhibitor can be orally administered in a hyperuricemia treating amount from about 1 to about 1000 mg per day, preferably from about 2 to about 400 mg/day, preferably 2.5 to about 75 mg/day, and more preferably 20 to about 50 mg/day, which can be administered in a single dose or in the form of individual doses from 1 to 4 times per day.

[0033] In certain embodiments of the methods of the invention, the SGLT2 inhibitor is advantageously administered in conjunction with a supply of carbohydrate to a mammal in need of a hyperuricemia treatment. Without being limited to particular mechanisms, the combination of an SGLT2 inhibitor and a supply of carbohydrate can further promote osmotic excretion of glucose. Without being limited to a particular mechanism, the beneficial effects of higher local concentration of glucose in the kidney due to the effects of the SGLT2 inhibitor and further enhanced by the supply of carbohydrate may be two fold: the elevated local concentration of glucose in the kidney may prevent the re-adsorption of uric acid back into the blood stream, and the increased osmotic excretion of glucose increases water release in the urine, which facilitates the excretion of excess uric acid into the urine. The invention also provides pharmaceutical compositions or pharmaceutical combinations for treating hyperuricemia comprising a therapeutically effective amount of an SGLT2 inhibitor. In yet another aspect, the invention provides pharmaceutical compositions for treating hyperuricemia comprising a therapeutically effective amount of an SGLT2 inhibitor and an inhibitor of uric acid synthesis. Advantageously, the pharmaceutical composition may further comprise a supply of carbohydrate. In certain embodiments of this aspect, the SGLT2 inhibitor is dapagliflozin. In further embodiments, the SGLT2 inhibitor is dapagliflozin PGS. In certain other embodiments, the SGLT2 inhibitor is remogliflozin, remogliflozin etabonate, sergliflozin or sergliflozin etabonate.

[0034] Other SGLT2 inhibitors suitable for use in this aspect of the invention are described throughout the specification, including without limitation AVE2268, TS-033, YM-543, BI 10773, BI 44847, and TA-7284. In certain embodiments, the pharmaceutical compositions further comprise at least one pharmaceutically-acceptable carrier, excipient or diluent. The invention provides methods for treating hyperuricemia comprising administering to a mammal in need thereof a pharmaceutical composition of the invention.

[0035] The SGLT2 inhibitors suitable for use in accordance with the invention also can be administered by injection to a patient in a hyperuricemia treating amount from about 1 to about 100 mg/day, preferably from about 1 to about 30 mg/day.

[0036] The SGLT2 inhibitors employed in the invention are most preferably selective for SGLT2 relative to SGLT-1. High selectivity for SGLT2, as is the case with dapagliflozin, is advantageous for use in the current invention because it avoids the unpredictable effects of intestinal SGLT1 inhibition.

[0037] Selectivity for SGLT2 of a given inhibitor can be determined by comparing the EC_{50} values measured in the SGLT1 and SGLT2 assay. Briefly, Human SGLT1 (hSGLT1) and human SGLT2 (hSGLT2) full-length cDNA sequences were cloned by PCR using MARATHON READY™ human kidney cDNA (Clontech, Mountain View, CA), with primers designed from published sequences (Genbank accession numbers NM_003041 and NM_000343). The hSGLT1 and hSGLT2 sequences were cloned into pIRESneo vector (Clontech, Mountain View, CA) for mammalian expression and were stably transfected into Chinese hamster ovary (CHO) cells. SGLT-expressing clones were selected based on resistance to G418 antibiotic (GENETICIN®, Invitrogen, Carlsbad, CA) and activity in the ^{14}C - α -methyl-D-glucopyranoside (^{14}C -AMG) uptake assay.

[0038] Cells expressing hSGLT1 or hSGLT2 were maintained using standard cell culture techniques. Assays for sodium-dependent glucose transport in 96-well plates were initiated by adding 100 μ l/well of protein-free assay buffer containing sodium (Hepes/Tris pH 7.4, 137 mM NaCl, 5.4 mM KCl, 2.8 mM $CaCl_2$, 1.2 mM $MgSO_4$) 10 μ M ^{14}C -AMG and inhibitor or dimethyl sulfoxide (DMSO) vehicle, and plates were incubated for 2 h at 37°C. Sodium-dependent ^{14}C -AMG uptake was calculated by subtracting the counts per minute (CPM) observed under sodium-free uptake conditions from the counts observed under sodium-containing conditions. Inhibitors were assayed at various concentrations in triplicate in the presence of sodium, and the percent inhibition was calculated by comparing CPM in inhibitor-containing wells with CPM in wells containing only DMSO vehicle. Phlorizin, a known SGLT inhibitor, was evaluated in parallel in every assay. A dose-response curve was fitted to an empirical four-parameter model using XL Fit (IDBS, Guilford, UK) to determine the inhibitor concentration at half-maximal response (EC_{50}). SGLT2 selectivity is represented as a ratio of

EC₅₀ in favor of SGLT2. An SGLT2 inhibitor with an EC₅₀ selective ratio of at least 10, and more preferably at least 100, in favor of SGLT2 is suitable for use in the instant invention.

[0039] The SGLT2 inhibitors suitable for use in accordance with the invention comprise C-arylglucosides or O-arylglucosides. SGLT2 inhibitors C-arylglucosides and O-arylglucosides are effective in treating diabetes. See U.S. Patent No. 6,774,112, which is incorporated herein by reference in its entirety. As disclosed herein, it was unexpectedly discovered that this class of SGLT2 inhibitors not only can increase glucose excretion in urine, but can also increase urine volume. Urinary excretion of glucose requires concomitant excretion of electrolyte-free water so that the final outcome produces a diuresis without releasing sodium to the urine. Thus, the methods of the invention using an SGLT2 inhibitor provide an effective treatment for hyperuricemia partly because it promotes a gradual release of electrolyte-free water in the process of glucose excretion in the urine. To the Applicant's knowledge, no other known anti-diabetic drugs in humans can cause glucosuria. Advantageously and unexpectedly, this class of SGLT2 inhibitors of the current invention increases urine volume over time. Without being limited to particular mechanisms, the increased urine volume may facilitate release of excess uric acid in the blood stream into urine. In certain embodiment of the invention, the SGLT2 inhibitor is a C-aryl glucoside.

[0040] Examples of C-arylglucoside (also referred to as C-glucosides) SGLT2 inhibitors which can be employed in the method of the invention, include, but are not limited to the following:

- 1) C-aryl glucosides as disclosed in U.S. Patent Nos. 6,515,117 and 6,414,126, the disclosures of which are incorporated herein by reference in their entirety for any purpose
- 2) C-aryl glucosides as described in U.S. Patent Application No. 11/233617 (U.S. Patent Application Publication No. 2006/0063722 A1), the disclosure of which is incorporated herein by reference in its entirety;
- 3) C-aryl glucosides described in U.S. Patent No. 6,774,112, the disclosure of which is incorporated herein by reference in its entirety;
- 4) Glucopyranosyl-substituted benzene derivatives as disclosed in U.S. Patent Application Publication No. 2005/0209166, the disclosure of which is incorporated herein by reference in its entirety;
- 5) D-pyranosyl-substituted phenyl compounds as disclosed in U.S. Patent Application Publication No. S 2006/0074031, the disclosure of which is incorporated herein by reference in its entirety;
- 6) D-xylopyranosyl-substituted compounds as disclosed in U.S. Patent Application Publication No. 2006/0035841, the disclosure of which is incorporated herein by reference in its entirety;
- 7) D-xylopyranosyl-substituted phenyl compounds as disclosed in U.S. Patent Application Publication No. 2006/0009400, the disclosure of which is incorporated herein by reference in its entirety;;
- 8) D-glucopyranosyl-phenyl-substituted compounds as disclosed in U.S. Patent Application Publication No. 2006/0025349, the disclosure of which is incorporated herein by reference in its entirety;
- 9) C-glycoside derivatives as disclosed in U.S. Patent Application Publication No. 2006/0122126, the disclosure of which is incorporated herein by reference in its entirety;
- 10) D-xylopyranosyl-substituted phenyl compounds as disclosed in U.S. Patent Application Publication No. 2006/0019948, the disclosure of which is incorporated herein by reference in its entirety;.

[0041] Examples of O-glucoside SGLT2 inhibitors which can be employed in the methods and pharmaceutical compositions of the invention include, but are not limited to those described in the the following:

- 1) 5-Thio-β-D-glucopyranoside as disclosed in U.S. Patent Application Publication No. 2006/0194809, the disclosure of which is incorporated by reference in its entirety for any purpose;
- 2) Glucopyranoxybenzene derivatives of as disclosed in WO 03/01180, the disclosure of which is incorporated by reference in its entirety for any purpose;
- 3) Pyrazole derivatives as disclosed in U.S. Patent No. 6,908,905, the disclosure of which is incorporated herein by reference for any purpose;
- 4) Pyrazole compounds as disclosed in U.S. Patent No. 6,815,428, the disclosure of which is incorporated herein by reference for any purpose;
- 5) O-glucosylated benzamide compounds as disclosed in U.S. Patent No. 6,555,519, the disclosure of which is incorporated herein by reference in its entirety for any purpose;
- 6) O-arylglucoside (or O-glucoside) compounds as disclosed in U.S. Patent No. 6,683,056, the disclosure of which is incorporated herein by reference in its entirety for any purpose;


[0042] Other O-aryl glucosides SGLT2 inhibitors which can be used in the invention are disclosed in the following references, each of which is incorporated herein by reference in its entirety for any purpose. EP 598359A1, EP 0850948A1, JP 09188625A, JP 09124685A, JP 09124684, EP 773226-A1, and JP 08027006-A, EP 684254-A1.

[0043] Other disclosures and publications disclosing SGLT2 inhibitors that can be employed in the methods and

pharmaceutical compositions of the invention are as follows: K. Tsujihara et al., Chem. Pharm. Bull., 44:1174-1180 (1996); M. Hongu et al., Chem. Pharm. Bull., 46:22-33 (1998); M. Hongu et al., Chem. Pharm. Bull., 46:1545-1555 (1998); and A. Oku et al., Diabetes, 48:1794-1800 (1999) and JP 10245391 (Dainippon).


[0044] Preferred SGLT2 inhibitors that can be employed in the present invention include dapagliflozin, remigliflozin, antisense oligonucleotide ISIS 388626, sergliflozin and those disclosed in U.S. Patent Application Publication No. 2005/0233982 (Boehringer Ingelheim Corp.), U.S. Patent Application Publication No. 2005/0119192 (Kissei Pharmaceutical Co.), WO 2006/035796 (Kissei Pharmaceutical Co.), JP 2006/117651 (Taisho Pharmaceutical Co.), JP 2004/4359630 (Yamanouchi Pharmaceutical Co.), WO 2006/080421 (Chugai Seiyaku Kabushiki Kaishi), U.S. Patent Application Publication No. 2005/0233988 (Tanabe Seiyaku Co.), WO 2005/012321 (Tanabe Seiyaku Co.), U.S. Patent No. 7,015,201 (Ajinomoto Co.), WO 2006/058597 (Merck Patent GmbH), WO 2006/011469 (Chugai Seiyaku Kabushiki Kaisha), US 2003/0195235 (Johnson & Johnson), and WO 2006/037537 (Boehringer Ingelheim), the disclosure of each of which is herein incorporated by reference in its entirety for any purpose.

[0045] In a preferred aspect, the invention provides SGLT2 inhibitors for use in the methods and pharmaceutical compositions of the invention that are disclosed in U.S. Patent Nos. 6,414,126 and 6,515,117, more preferably the SGLT2 inhibitor is compound I or dapagliflozin




or a pharmaceutically acceptable salt thereof, all stereoisomers thereof, or a prodrug ester thereof.

[0046] In another preferred aspect, the invention provides an SGLT2 inhibitor for use in the methods and pharmaceutical compositions of the invention that is compound IIIA




or a pharmaceutically acceptable salt thereof, all stereoisomers thereof, or a prodrug ester thereof.

[0047] In another preferred aspect, the invention provides an SGLT2 inhibitor for use in the methods and pharmaceutical compositions of the invention that is compound II



or a pharmaceutically acceptable salt thereof, all stereoisomers thereof, or a prodrug ester thereof.

[0048] In another preferred aspect, the invention provides crystalline forms of compound I including the crystalline forms disclosed in U.S. Application Serial No. 11/765481, the disclosure of which is incorporated herein by reference in its entirety for any purpose. A most preferred crystalline form for use in the methods and pharmaceutical compositions of the invention is the (S)-propylene glycol solvate of the compound of formula I, namely Compound Ia or dapagliflozin PGS



Compound Ia or dapagliflozin PGS is prepared as described in U.S. Application Serial No. 11/765481, published as U.S. Patent Application Publication No. 2008/0004336, which is incorporated by reference herein.

[0049] The SGLT2 inhibitor employed in accordance with the invention can be administered to various mammalian species, such as dogs, cats, cattle, humans, etc., in need of treatment. These agents can be administered systemically, such as orally or parenterally.

[0050] The invention also provides pharmaceutical compositions that comprise compounds of the invention formulated together with one or more pharmaceutically acceptable carriers. The pharmaceutical compositions can be specially formulated for oral administration in solid or liquid form, for parenteral injection or for rectal administration.

[0051] The pharmaceutical compositions of this invention can be administered to humans and other mammals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, buccally or as an oral or nasal spray. The term "parenterally," as used herein, refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

[0052] The SGLT-2 inhibitor can be incorporated in a conventional systemic dosage form, such as a tablet, capsule, elixir or injectable formulation. The above dosage forms will also include the necessary physiologically acceptable carrier material, excipient, lubricant, buffer, antibacterial, bulking agent (such as mannitol), antioxidants (ascorbic acid or sodium bisulfite) or the like. Oral dosage forms are preferred, although parenteral forms are quite satisfactory as well.

[0053] Pharmaceutical compositions of this invention for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol and the like), vegetable oils (such as olive oil), injectable organic esters (such as ethyl oleate) and suitable mixtures thereof. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.

[0054] These compositions may also contain adjuvants such as preservative, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms can be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

[0055] In some cases, in order to prolong the effect of the drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This can be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

[0056] Injectable depot forms are made by forming microcapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.

[0057] The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile

water or other sterile injectable medium just prior to use.

[0058] Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier, such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol and silicic acid; b) binders such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; c) humectants such as glycerol; d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate; e) solution retarding agents such as paraffin; f) absorption accelerators such as quaternary ammonium compounds; g) wetting agents such as cetyl alcohol and glycerol monostearate; h) absorbents such as kaolin and bentonite clay and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

[0059] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

[0060] The solid dosage forms of tablets, dragees, capsules, pills and granules can be prepared with coatings and shells such as enteric coatings and other coatings well-known in the pharmaceutical formulating art. They may optionally contain opacifying agents and may also be of a composition such that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

[0061] The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.

[0062] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan and mixtures thereof.

[0063] Besides inert diluents, the oral compositions may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents.

[0064] Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, tragacanth and mixtures thereof.

[0065] The dose administered is adjusted according to the age, weight, and condition of the patient, as well as the route of administration, dosage form and regimen, and the desired result. In general, the dosage forms described above can be administered containing amounts of SGLT-2 inhibitor of from about 1 to about 1000 mg per day preferably from about 2 to about 400 mg per day, in single or divided doses of one to four times daily.

[0066] Unless otherwise indicated, dosages and formulations for SGLT2 inhibitors used in the methods set forth herein are disclosed in the various patents and applications discussed throughout the application, which are incorporated herein in their entireties.

[0067] The various formulations of the invention can optionally include one or more fillers or excipients in an amount within the range of from about 0 to about 90% by weight and preferably from about 1 to about 80% by weight such as lactose, sugar, corn starch, modified corn starch, mannitol, sorbitol, inorganic salts such as calcium carbonate and/or cellulose derivatives such as wood cellulose and microcrystalline cellulose.

[0068] One or more binders can be present in addition to or in lieu of the fillers in an amount within the range of from about 0 to about 35% and preferably from about 0.5 to about 30% by weight of the composition. Examples of such binders suitable for use herein include polyvinylpyrrolidone (molecular weight ranging from about 5000 to about 80,000 and preferably about 40,000), lactose, starches such as corn starch, modified corn starch, sugars, gum acacia and the like as well as a wax binder in finely powdered form (less than 500 microns) such as carnauba wax, paraffin, spermaceti, polyethylenes or microcrystalline wax.

[0069] Where the composition is in the form of a tablet, it may include one or more tableting lubricants in an amount within the range of from about 0.2 to about 8% and preferably from about 0.5 to about 2% by weight of the composition, such as magnesium stearate, stearic acid, palmitic acid, calcium stearate, talc, carnauba wax and the like. Other conventional ingredients that can optionally be present include preservatives, stabilizers, anti-adherents or silica flow conditioners or glidants, such as Syloid brand silicon dioxide as well as FD&C colors.

[0070] Tablets of the invention can also include a coating layer that can comprise from 0 to about 15% by weight of the tablet composition. The coating layer can comprise any conventional coating formulations and include one or more film-formers or binders, such as a hydrophilic polymer like hydroxypropylmethylcellulose, and/or a hydrophobic polymer like methacrylic acid esters neutral polymer, ethyl cellulose, cellulose acetate, polyvinyl alcohol-maleic anhydride copolymers, β -pinene polymers, glyceryl esters of wood resins and the like and one or more plasticizers, such as triethyl

citrate, diethyl phthalate, propylene glycol, glycerin, butyl phthalate, castor oil and the like. Both core tablets as well as coating formulations can contain aluminum lakes to provide color.

[0071] The film formers are applied from a solvent system containing one or more solvents including water, alcohols like methyl alcohol, ethyl alcohol or isopropyl alcohol, ketones like acetone, or ethylmethyl ketone, chlorinated hydrocarbons like methylene chloride, dichloroethane, and 1,1,1-trichloroethane.

[0072] Where a color is employed, the color is applied together with the film former, plasticizer and solvent compositions.

[0073] It will be recognized by one of skill in the art that the amount of drug required for therapeutic effect on administration will, of course, vary with the agent chosen, the nature and severity of the condition and the mammal undergoing treatment, and is ultimately at the discretion of the physician. Furthermore, the optimal quantity and spacing of individual dosages of a drug will be determined by the nature and extent of the therapeutic effects desired, the form, route and site of administration, the particular patient being treated and that such optima can be determined by conventional techniques. It will also be appreciated that the optimal course of treatment, for example, the number of doses given, can be ascertained by those skilled in the art using conventional course of treatment determination tests.

[0074] Preferred tablet and capsule formulations in accordance with the invention are set out below in Table 2.

Table 2 Tablet and Capsule Formulations

Material	Range	Preferred Range
Tablet	%/mg by weight of 200 mg tablet	%/mg by weight of 200 mg tablet
Dapagliflozin	0.1 to 70% / 0.2 to 140 mg	1 to 50% / 2 to 100 mg
Bulking Agent	2 to 95% / 4 to 190 mg	10 to 85% / 20 to 170 mg
Lactose	0 to 95% / 0 to 190 mg	20 to 75% / 10 to 100 mg
Microcrystalline cellulose	0 to 95% / 0 to 190 mg	20 to 75% / 40 to 150 mg
Disintegrant	0 to 20% / 0 to 40 mg	0.25 to 10% / 0.5 to 20 mg
Croscarmellose sodium	0 to 20% / 0 to 40 mg	2 to 10% / 4 to 20 mg
Crospovidone	4 to 12% / 4 to 20 mg	6 to 10% / 12 to 20 mg
Lubricant	0.1 to 5% / 0.2 to 10 mg	0.2 to 2% / 0.4 to 4 mg
Magnesium Stearate	0.1 to 5% / 0.2 to 10 mg	0.2 to 2% / 0.4 to 4 mg
Anti adherent/glidant Talc, silicon dioxide	0 to 10% / 0 to 20 mg	1 to 4% / 2 to 8 mg
Outer Protective Coating Layer	% / mg by weight of 200 mg tablet	% / mg by weight of 200 mg tablet
Coating polymer, and optional Plasticizer, glidants and color	0.5 to 50% / 1 to 100 mg	1 to 5% / 2 to 10 mg

[0075] Preferred stock granulation formulations (for use in capsules) in accordance with the invention are set out below in Table 3.

Table 3

Material	Range	Preferred Range
Tablet	% / mg by weight of 200 mg tablet	% / mg by weight of 200 mg tablet
Dapagliflozin	0.1 to 70% / 0.2 to 140 mg	1 to 50% / 2 to 100 mg
Bulking Agent/Binder	2 to 95% / 4 to 190 mg	10 to 85% / 20 to 170 mg
Microcrystalline cellulose	1 to 95% / 1 to 190 mg	20 to 75% / 10 to 100 mg
Pregelatinized starch	0 to 95% / 0 to 190 mg	20 to 75% / 40 to 150 mg
Disintegrant	0 to 20% / 0 to 40 mg	0.25 to 10% / 0.5 to 20 mg
Sodium Starch glycolate	0 to 20% / 0 to 40 mg	2 to 10% / 4 to 20 mg

(continued)

5	Material Tablet Dapagliflozin	Range % / mg by weight of 200 mg tablet 0.1 to 70% / 0.2 to 140 mg	Preferred Range % / mg by weight of 200 mg tablet 1 to 50% / 2 to 100 mg
	Lubricant	0.1 to 5% / 0.2 to 10 mg	0.2 to 2% / 0.4 to 4 mg
	Magnesium Stearate	0.1 to 5% / 0.2 to 10 mg	0.2 to 2% / 0.4 to 4 mg
10	Anti adherent/glidant Talc silicon dioxide	0 to 10% / 0 to 20 mg	1 to 4% / 2 to 8 mg

[0076] A typical injectable preparation is produced by aseptically placing 50 mg of compounds of the present invention into a vial, aseptically freeze-drying and sealing. For use, the contents of the vial are mixed with 2 mL of physiological saline, to produce an injectable preparation.

[0077] SGLT2 inhibitor activity of the compounds of the invention can be determined by use of an assay system as set out below.

ASSAY FOR SGLT2 ACTIVITY

[0078] The mRNA sequence for human SGLT2 was cloned by reverse-transcription and amplification from human kidney mRNA, using standard molecular biology techniques. The cDNA sequence was stably transfected into CHO cells, and clones were assayed for SGLT2 activity essentially as described in Ryan et al., 1994, "HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney," *Kidney International* 45:48-57. Evaluation of inhibition of SGLT2 activity in a clonally selected cell line was performed essentially as described in Ryan *et al.*, with the following modifications. Cells were grown in 96-well plates for 2-4 days to 75,000 or 30,000 cells per well in F-12 nutrient mixture (Ham's F-12; GIBCO, Long Island, NY), 10% fetal bovine serum, 300 µg/ml Geneticin and penicillin-streptomycin. At confluence, cells were washed twice with 10 mM Hepes/Tris, pH 7.4, 137 mM N-methyl-D-glucamine, 5.4 mM KCl, 2.8 mM CaCl₂, 1.2 mM MgSO₄. Cells then were incubated with 10 µM [¹⁴C]AMG, and 10 µM inhibitor (final DMSO = 0.5%) in 10 mM Hepes/Tris, pH 7.4, 137 mM NaCl, 5.4 mM KCl, 2.8 mM CaCl₂, 1.2 mM MgSO₄ at 37°C for 1.5 hr. Uptake assays were quenched with ice cold 1X PBS containing 0.5 mM phlorizin, and cells were then lysed with 0.1 % NaOH. After addition of MicroScint scintillation fluid, the cells were allowed to shake for 1 hour, and then [¹⁴C]AMG was quantified on a TopCount scintillation counter. Controls were performed with and without NaCl. For determination of EC₅₀ values, 10 inhibitor concentrations were used over 2 log intervals in the appropriate response range, and triplicate plates were averaged across plates. Ryan *et al.*, *Id.*

EXAMPLES

[0079] The following working Examples are illustrative of the invention. All temperatures are expressed in degrees Centigrade unless otherwise indicated.

EXAMPLES 1 TO 3

[0080] Capsules containing the SGLT2 inhibitor of Formula I (dapagliflozin) were prepared in strengths of 2.5 mg (Example 1), 10 mg (Example 2) and 100 mg (Example 3) (as the non-solvated form) as two-piece, gray opaque size #0 (2.5 mg and 10 mg) and size #00 (for 0 mg) hard gelatin capsules.

EXAMPLES 1 AND 2

[0081] Composition: 25.0 mg of Granulation containing dapagliflozin for Capsules (10.0% w/w as the non-solvated form), filled in Gray, Opaque, Size #0 Capsule Shell.

A. Stock Granulation Composition

[0082]

EP 2 668 953 A1

Ingredient	Amount (% w/w)
Dapagliflozin PGS ¹	10.0
Pregelatinized Starch, NF	15.0
Microcrystalline Cellulose, NF ²	68.75
Sodium Starch Glycolate, NF	3.0
Silicon Dioxide, NF	2.0
Magnesium Stearate, NF ³	1.25
¹ This amount is expressed in terms of the amount of the dapagliflozin at 100% purity. The exact amount will vary depending on the purity of the dapagliflozin. ² The amount of microcrystalline cellulose used will vary depending on the purity of the dapagliflozin. ³ The preferred amount is 1.25% (w/w). The range is 1.25-1.50% (w/w).	

[0083] The stock granulation of Part A and the Example 1 and Example 2 capsules were prepared according to the following procedures.

EXAMPLE 1

B. Example 1 Stock granulation procedure

[0084]

1. Screen dapagliflozin.
2. Screen silicon dioxide.
3. Mix silicon dioxide with dapagliflozin in a suitable blender.
4. Screen pregelatinized starch and microcrystalline cellulose, if necessary.
5. Add ingredients from Step 4 to a suitable blender.
6. Add mixture from Step 3 to the blend from Step 5, and mix.
7. Screen sodium starch glycolate.
8. Add ingredient from Step 7 to the blend from Step 6, and mix.
9. Screen the blend from Step 8, and mix.
10. Screen portion of magnesium stearate.
11. Add ingredient from Step 10 to the blend from Step 9, and mix.
12. Densify the blend from Step 11.
13. Reduce the densified blend Step 12.
14. Screen the remaining portion of magnesium stearate.
15. Add ingredient from Step 14 to the granulation from Step 13, and mix.

C. Example 1 Product: Dapagliflozin Capsule, 2.5 mg (As the Non-solvated Form)

[0085]

1. Fill empty capsule shells with sufficient Example 1 Part A stock granulation for capsules (10.0%) w/w (as the non-solvated form), to provide 2.5 mg capsules.
2. De-dust the capsules.

EXAMPLE 2

Product: Dapagliflozin Capsule, 10 mg (As the Non-solvated Form)

[0086]

EP 2 668 953 A1

1. Fill empty capsule shells with Example 1 Part A stock granulation for capsules (10.0 % w/w as the non-solvated form), to provide 10 mg capsules.
2. De-dust the capsules.
3. Weight sort the capsules.

[0087] The Example 1 (2.5 mg) and Example 2 (10 mg) capsules are used in treating obesity.

EXAMPLE 3

Dapagliflozin Capsule, 100 mg (As the Non-solvated Form)

[0088] Composition: 438.6 mg of dapagliflozin (Example 3 Part A) Stock Granulation for Capsules (22.8% w/w as the non-solvated form), filled in Gray, Opaque, Size #0 Capsule Shell.

A. Stock Granulation Composition

[0089]

Ingredient	Amount (% w/w)
Dapagliflozin PGS ¹	22.8
Pregelatinized Starch, NF	15.0
Microcrystalline Cellulose, NF ²	55.95
Sodium Starch Glycolate, NF	3.0
Silicon Dioxide, NF	2.0
Magnesium Stearate, NF ³	1.25
¹ This amount is expressed in terms of the amount of the dapagliflozin at 100% purity. The exact amount will vary depending on the purity of the dapagliflozin. ² The amount of microcrystalline cellulose used will vary depending on the purity of the dapagliflozin. ³ The preferred amount is 1.25% (w/w). The range is 1.25-1.50% (w/w).	

[0090] The stock granulation of Part A and the Example 3 capsules were prepared according to the following procedures.

B. Stock Granulation Procedure

[0091]

1. Screen silicon dioxide.
2. Mix silicon dioxide with dapagliflozin in a suitable blender.
3. Screen the blend from Step 2, and mix again.
4. Screen pregelatinized starch and microcrystalline cellulose, if necessary.
5. Add ingredients from Step 4 to the blend from Step 3, and mix.
6. Screen sodium starch glycolate.
7. Add ingredient from Step 6 to the blend from Step 5, and mix.
8. Screen a portion of magnesium stearate.
9. Add ingredient from Step 8 to the blend from Step 7, and mix.
10. Densify the blend from Step 9.
11. Reduce the densified blend from Step 10.
12. Screen the remaining portion of magnesium stearate.
13. Add ingredient from Step 12 to the granulation from Step 11, and mix.

C. Example 3 Product: Dapagliflozin Capsule, 100 mg (As the Non-solvated Form)**[0092]**

1. Fill empty capsule shells with Example 3 stock granulation for capsules (22.8 % w/w as the non-solvated form).
2. De-dust the capsules.
3. Weight sort the capsules.

EXAMPLES 4 TO 6

[0093] Tablets containing the SGLT2 inhibitor of formula Ia (dapagliflozin (S)-propylene glycol solvate (PGS) (or dapagliflozin PGS) were prepared in strengths of 2.5 mg (Example 4), 10 mg (Example 5) and 50 mg (Example 6) as described below.

EXAMPLE 4**Product: Dapagliflozin PGS Tablet, 2.5 mg****A. Tablet Composition****[0094]**

Ingredient	Amount
Dipagliflozin PGS ¹	3.075 mg
Microcrystalline Cellulose, NF ²	67.113 mg
Lactose Anhydrous, NF	25.000mg
Croscopovidone, NF	8.750 mg
Croscarmellose Sodium, NF	3.750 mg
Talc, USP	12.500 mg
Silicon Dioxide, NF	2.875 mg
Magnesium Stearate, NF ³	1.938 mg
¹ Dapagliflozin PGS is a propylene glycol solvate. The amount of non-solvated dapagliflozin is theoretically equivalent to 81.29% of dapagliflozin PGS. The actual amount of dapagliflozin PGS will depend on the "As Is" purity of the drug. ² This is the compensating excipient. The amount used may vary depending on the "As Is" purity of the drug and/or the actual amount of magnesium stearate used. ³ The target amount is 1.94 mg. Acceptable range is 1.55-2.33 mg.	

[0095] The stock granulation of Part A and the Example 4 tablets were prepared according to the following procedures.

B. Stock Granulation Procedure**[0096]**

1. Deaggregate dapagliflozin PGS and magnesium stearate separately using a suitable screen.
2. Mix dapagliflozin PGS with a portion of microcrystalline cellulose in a suitable mixer and transfer it into a suitable blender.

EP 2 668 953 A1

3. "Dry Rinse" the mixer used for mixing Step 2 with a portion of microcrystalline cellulose.
4. Add the blend from Step 3 to the blend from Step 2.
5. Mix the mixture from Step 4 with remaining microcrystalline cellulose, portion of croscopovidone, portion of croscarmellose sodium, portion of silicon dioxide and lactose anhydrous.
6. Add talc and intragranular magnesium stearate to the mixture from Step 5 and mix.
7. Compact the powder blend from Step 6.
8. Reduce compact from Step 7 to form granules.
9. Mix the granules from Step 8 with remaining amounts of croscopovidone, croscarmellose sodium and silicon dioxide.
10. Mix the granules from Step 9 with remaining amount of magnesium stearate.

C. Example 4 Product: Dapagliflozin PGS Tablet, 2.5 mg

[0097]

1. Setup the tableting equipment.
2. Compress the Example 4 stock granulation into tablets (2.46% w/w), (2.5 mg).

EXAMPLE 5

Product: Dapagliflozin PGS Tablet, 10 mg

A. Tablet Composition

[0098]

Ingredient	Amount
Dapagliflozin PGS ¹	12.300 mg
Microcrystalline Cellulose, NF ²	57.888 mg
Lactose Anhydrous, NF	25.000 mg
Croscopovidone, NF	8.750 mg
Croscarmellose Sodium, NF	3.750 mg
Talc, USP	12.500 mg
Silicon Dioxide, NF	2.875 mg
Magnesium Stearate, NF ³	1.938 mg

¹ Dapagliflozin PGS is a propylene glycol solvate. The amount of non-solvated dapagliflozin PGS is theoretically equivalent to 81.29% of dapagliflozin PGS. The actual amount of dapagliflozin PGS will depend on the "As Is" purity of the drug.

² This is the compensating excipient. The amount used may vary depending on the "As Is" purity of the drug and/or the actual amount of magnesium stearate used.

³ The target amount is 1.94 mg. Acceptable range is 1.55-2.33 mg.

[0099] The stock granulation of Part A and the Example 5 tablets were prepared according to the following procedures.

B. Stock Granulation Procedure

[0100]

EP 2 668 953 A1

1. Deaggregate dapagliflozin PGS and magnesium stearate separately using a suitable screen.
2. Mix microcrystalline cellulose, dapagliflozin PGS portion of crospovidone, portion of croscarmellose sodium, portion of silicon dioxide and lactose anhydrous in a suitable blender.
3. Add talc and intragranular magnesium stearate to the mixture from Step 2 and mix in a suitable blender.
4. Compact the powder blend from Step 3.
5. Reduce compact from Step 4 to form granules.
6. Mix the granules from Step 5 with remaining amounts of crospovidone, croscarmellose sodium and silicon dioxide.
7. Mix the granules from Step 6 with remaining amount of magnesium stearate.

C. Example 5 Product: Dapagliflozin Propylene Glycol Solvate (PGS) Tablet, 10 mg

[0101]

1. Setup the tableting equipment.
2. Compress the Example 5 stock granulation into tablets (9.84% w/w).

EXAMPLE 6

Product: Dapagliflozin PGS Tablet, 50 mg

A. Tablet Composition

[0102]

Ingredient	Amount
Dapagliflozin PGS ¹	61.660 mg
Microcrystalline Cellulose, NF ²	114.090 mg
Lactose Anhydrous, NF	62.600 mg
Crospovidone, NF	21.910 mg
Croscarmellose Sodium, NF	9.390 mg
Talc, USP	31.300 mg
Silicon Dioxide, NF	7.200 mg
Magnesium Stearate, NF ³	4.850 mg
¹ The amount shown is based on the amount of dapagliflozin PGS at 100% purity. The exact amount may vary depending on the "As Is" purity of the dapagliflozin PGS. ² This is the compensating excipient. The amount used may vary depending on the "As Is" purity of the drug and/or the actual amount of magnesium stearate used. ³ The target amount is 4.85 mg. Acceptable range is 3.76 - 5.95 mg.	

[0103] The stock granulation of Part A and the Example 6 tablets were prepared according to the following procedures.

B. Stock Granulation Procedure

[0104]

1. Mix dapagliflozin PGS microcrystalline cellulose, lactose anhydrous, crospovidone, croscarmellose sodium, talc and silicon dioxide in a suitable blender.
2. Pass the mixture from Step 1 through a suitable mill.

3. Determine the yield from Step 1 and calculate the amount of magnesium stearate required.
4. Mix the mixture from Step 2 in a suitable blender.
5. Mix the mixture from Step 4 with magnesium stearate.
6. Dry granulate the powder blend from Step 5.
7. Size the granulation from Step 6.
8. Determine the yield based on Step 7.
9. Mix the granules from Step 8 with remaining amount of croscopovidone, croscarmellose sodium and silicon dioxide.
10. Mix the granules from Step 9 with remaining amount of magnesium stearate.

C. Example 6 Product: Dapagliflozin PGS Tablet, 50 mg

[0105]

1. Setup the tableting equipment.
2. Compress the Example 6 stock granulation (19.7% w/w), into tablets (50 mg).

EXAMPLE 7

SGLT2 inhibitor dapagliflozin PSG increases urinary excretion of glucose in healthy subjects


[0106] The glucosuric effects of dapagliflozin PGS results in significant loss of calories in the urine as compared to a known SGLT2 inhibitor (GSK 869,682). As seen in Figure 1, the results of an indirect comparison of two single ascending dose studies of SGLT2 inhibitors are shown. The panel at the top of Figure 1 shows the amount of glucose excretion/day within 24 hours in healthy subjects taking 50, 100, 200 or 500 mg of GSK 869,682. The panel at the bottom shows the amount of glucose excretion/day within 24 hours in healthy subjects taking 5, 20, 50 or 100 mg of dapagliflozin PGS.

[0107] In a similar experiment, the effects of the C-arylglucoside dapagliflozin PGS and two O-arylglucosides on urine glucose excretion in healthy individuals were compared. The results are shown in Table 4.

Table 4

Urinary Glucose Excretion over 24 hr in Healthy Normal Volunteers Following Administration of Selected SGLT2 Inhibitors		
Drug	Dose	Glucose Output over 24 hr
Sergliflozin-A (O-glucoside)*	200 mg	12 g
	500 mg	17 g
AVE 2268 (O-glucoside)	1200 mg	14 g
	2000 mg	21 g
Dapagliflozin (C-glucoside)	5 mg	~ 32 g
	20 mg	~ 64 g

* Sergliflozin-A (GSK 869682) has the following structure



EXAMPLE 8**SGLT2 inhibitor dapagliflozin PGS increases urinary excretion of glucose over a 24 hour period in patients with diabetes**

[0108] In a separate study, patients with diabetes were treated with dapagliflozin PGS at dose of 5, 25, or 100 mg or treated with placebo. The amount of urinary glucose excretion (g/day) was plotted as a function of time and is shown in Figure 2. The levels of urine glucose of all subjects are shown in the plot and the mean urine glucose is in the darker lines. Compared to subjects treated with placebo, subjects treated with dapagliflozin PGS showed higher levels of urine glucose excretion.

EXAMPLE 9**Patient treated with SGLT2 inhibitor dapagliflozin for 12 weeks exhibited increased urine volume and reduced serum uric acid levels**

[0109] C-aryl glucoside SGLT2 inhibitors are known to reduce blood glucose levels in diabetic patients, see U.S. Patent No. 6,774,112, which is incorporated herein by reference in its entirety, but not known to increase urine volume. In this experiment, the effects of dapagliflozin PGS on glucosuria and urine volume were examined. 47 drug-naïve or metformin-treated type 2 diabetic patients with fasting serum glucose levels no greater than 240 mg/dL were included in the study. Metformin reduces plasma glucose concentration by non-renal mechanisms and is not known to induce glucosuria. The patients received various amounts of dapagliflozin PGS or placebo on day zero. On day 1 and day 14, the patients were examined for the levels of glucosuria and changes in urine volumes. As shown in Figure 3, urinary glucose levels increased within a 24-hour time period in dapagliflozin-treated, but not in placebo-treated, subjects. Within the dapagliflozin-treated group, the constant rate of glucosuria over 24 hours was estimated to be about 2 g/hr and 48 g/d (5 mg dapagliflozin PGS) and about 3 g/hr and 72 g/d (25 mg and 100 mg dapagliflozin PGS). Dose-dependent reduction in fasting serum glucose (FSG) levels, and reduced postprandial glucose levels in oral glucose tolerance tests (OGTT) were also observed in dapagliflozin-treated patients. Although both FSG and OGTT responses improved over a two-week period of time, no increase in urine volumes was apparent during the same time period. Patients' serum uric acid levels were not measured in this experiment.

[0110] Urine volume increases were observed in patients with prolonged treatment of dapagliflozin PGS. In a separate experiment, diabetic patients were treated with 2.5 mg, 5 mg, 10 mg, 20 mg, and 50 mg dapagliflozin PGS for 12 weeks (N = 389, body mass index (BMI) > 30, with glycosylated hemoglobin HbA1C levels around 7.7-8.0%). After 12 weeks of treatment, the patient excreted 50-60 g glucose in urine every day, and showed improved OGT and reduced HbA1C levels (0.71-0.9%, similar to patients treated with 1500 mg metformin, which showed HbA1C levels at 0.73 %). Significantly, the patients treated with dapagliflozin PGS for 12 weeks showed a 5-20 % increase in urine volume. Further, patients received dapagliflozin PGS at all concentrations exhibit a decrease of serum uric acid levels after 12 weeks treatment. See Table 5. The average of decrease in serum uric acid levels was approximately 1 mg/dL, while patients received placebo exhibited a reduction of serum uric acid by only 0.16 mg/dL. Thus, dapagliflozin PGS decreased serum uric acid levels and can be used as a treatment for hyperuricemia.

Table 5 Dapagliflozin PGS reduced serum uric acid in individuals after 12 week-treatment

dapagliflozin PGS (mg)	2.5	5	10	20	50	placebo	metformin
Uric Acid (me/dL)	-1.03±0.81	-1.12±0.84	-0.98±0.66	-1.13±0.78	-1.14±1.15	-0.16±0.75	0.18±0.53
p-value vs. placebo	<0.0001	<0.0001	<0.0001	<0.0001	<0.0001		
Values are means ± standard deviation.							

[0111] Thus, the present invention, in particular, discloses to the following embodiments E1-E15:

E1. A method for treating hyperuricemia in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a sodium glucose transporter 2 (SGLT2) inhibitor.

E2. The method according to E1 wherein the mammal is a human.

E3. The method according to E2, wherein the human has gout as a result of hyperuricemia, and the method for treating hyperuricemia prevents the symptoms of gout in the human.

E4. The method according to E1, said method further comprising administering to the mammal a supply of carbohydrate, wherein the supply of carbohydrate is administered before, after, or concurrently with the SGLT2 inhibitor.

E5. The method according to E1, further comprising administering to the mammal an inhibitor of uric acid synthesis wherein the inhibitor of uric acid synthesis is administered before, after, or concurrently with the SGLT2 inhibitor.


E6. The method according to E4, wherein the inhibitor of uric acid synthesis is a xanthine oxidase inhibitor.

E7. The method according to E1, wherein the SGLT2 inhibitor is a C-aryl glucoside or an O-aryl glucoside.

E8. The method according to E7, wherein the SGLT2 inhibitor is a C-aryl glucoside.

E9. The method according to E1, wherein the SGLT2 inhibitor is administered in an amount sufficient to treat hyperuricemia without inducing hypoglycemia.

E10. The method according to E1, wherein the SGLT2 inhibitor is



or a pharmaceutically acceptable salt, a stereoisomer, or a prodrug ester thereof wherein


R¹, R² and R^{2a} are independently hydrogen, OH, OR⁵, alkyl, CF₃, OCHF₂, OCF₃, SR⁵ⁱ or halogen, or two of R¹, R² and R^{2a} together with the carbons to which they are attached can form an annelated five, six or seven membered carbocycle or heterocycle which may contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO₂, R³ and R⁴ are independently hydrogen, OH, OR^{5a}, OAr^{yl}, OCH₂Ar^{yl}, alkyl, cycloalkyl, CF₃, -OCHF₂, -OCF₃, halogen, -CN, -CO₂R^{5b}, -CO₂H, COR^{6b}, -CH(OR)^{6c}, -CH(OR^{5h})R^{6d}, -CONR^{6a}, -NHCOR^{5c}, -NHCO₂R^{5d}, -NHCO₂Ar^{yl}, Ar^{yl}, -SR^{5e}, -SOR^{5f}, -SO₂R^{5g}, -SO₂Ar^{yl}, or a five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO₂, or R³ and R⁴ together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle which may contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO₂,

R⁵, R^{5a}, R^{5b}, R^{5c}, R^{5d}, R^{5e}, R^{5f}, R^{5g}, R^{5h} and R⁵ⁱ are independently alkyl;

R⁶, R^{6a}, R^{6b}, R^{6c}, and R^{6d} are independently hydrogen, alkyl, aryl, alkylaryl or cycloalkyl, or R⁶ and R^{6a} together with the nitrogen to which they are attached form an annelated five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO₂;


A is O, S, NH, or (CH₂)_n where n is 0-3, or a pharmaceutically acceptable salt, stereoisomer, or prodrug ester thereof; with the proviso that where A is (CH₂)_n where n is 0, 1, 2, or 3 or A is O, and at least one of R¹, R², and R^{2a} is OH or OR⁵, then at least one of R¹, R², and R^{2a} is CF₃, OCF₃, or OCHF₂ and/or at least one of R³ and R⁴ is CF₃, -OCHF₂, -OCF₃, -CN, -CO₂R^{5b}, CH(OR^{5h})R^{6d}, CH(OH)R^{6c}, COR^{6b}, -NHCOR^{5c}, -NHCO₂R^{5d}, -NHCO₂Ar^{yl}, Ar^{yl}, -SR^{5e}, -SOR^{5f}, -SO₂R^{5g} or -SO₂Ar^{yl}.

E11. The method according to E1 wherein the SGLT2 inhibitor is




or a stereoisomer, or a prodrug ester thereof.

E12 The method according to E1 wherein the SGLT2 inhibitor is



Compound 1a


E13 The method as defined in E1 wherein the SGLT2 inhibitor is



or a stereoisomer, or a prodrug ester thereof.

E14. A pharmaceutical composition comprising an SGLT2 inhibitor and an inhibitor of uric acid synthesis or a supply of carbohydrate.


E15. The pharmaceutical composition according to E14, wherein the SGLT2 inhibitor is




or a stereoisomer, or a pharmaceutically acceptable salt thereof, or a propylene glycol solvate thereof.

Claims

1. A pharmaceutical composition comprising an SGLT2 inhibitor and an inhibitor of uric acid synthesis or a supply of carbohydrate.
2. The pharmaceutical composition according to claim 1, comprising the SGLT2 inhibitor and the inhibitor of uric acid synthesis.
3. The pharmaceutical composition according to claim 2, wherein the inhibitor of uric acid synthesis is a xanthine oxidase inhibitor.
4. The pharmaceutical composition according to claim 2 or claim 3, further comprising the supply of carbohydrate.
5. The pharmaceutical composition according to claim 1, comprising the SGLT2 inhibitor and the supply of carbohydrate.
6. The pharmaceutical composition according to any of claims 1-5, wherein the SGLT2 inhibitor is



7. The pharmaceutical composition according to any of claims 1-5, wherein the SGLT2 inhibitor is provided as a propylene glycol solvate having the formula:



Compound Ia

8. The pharmaceutical composition according to any of claims 1-7, further comprising at least one pharmaceutically-acceptable carrier, excipient or diluent.
9. The pharmaceutical composition of any of claims 1-8 for use in treating hyperuricemia in a mammal.
10. The pharmaceutical composition for use according to claim 9, wherein the mammal is a human.
11. The pharmaceutical composition for use according to claim 10, wherein the human has gout as a result of hyperuricemia, and the treatment of hyperuricemia prevents the symptoms of gout in the human.

FIG. 1

Indirect comparison of GSK 869,682 and Dapagliflozin PGS in healthy individuals





FIG. 2

Urine glucose excretion in diabetic subjects treated with Dapagliflozin PGS





FIG. 3





EUROPEAN SEARCH REPORT

Application Number
EP 13 18 1659

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	WO 2008/055940 A2 (BOEHRINGER INGELHEIM INT [DE]; BOEHRINGER INGELHEIM PHARMA [DE]; MANUC) 15 May 2008 (2008-05-15)	1,2,4,5,8	INV. A61K31/7004 A61K31/351
Y	* examples a-c * * page 21, paragraph 4 *	3,6,7,9-11	A61P19/06 A61K45/06 A61K31/60
X,P	WO 2008/116179 A1 (BRISTOL MYERS SQUIBB [US]; BINDRA DILBIR S [US]; DALI MANDAR V [US]; P) 25 September 2008 (2008-09-25) * claim 5 *	1,5-8	
E	WO 2009/143021 A1 (SQUIBB BRISTOL MYERS CO [US]; ASTRAZENECA UK LTD [GB]; HALPERIN MITCHE) 26 November 2009 (2009-11-26) * claim 14 *	1,5-8	
X	WO 2007/093610 A (BOEHRINGER INGELHEIM INT [DE]; BOEHRINGER INGELHEIM PHARMA [DE]; ECKHA) 23 August 2007 (2007-08-23)	1,2,4-11	
Y	* claim 7 * * page 26, line 36 - line 37 * * page 39 *	3,6,7,9-11	TECHNICAL FIELDS SEARCHED (IPC)
Y	EP 1 698 635 A1 (KISSEI PHARMACEUTICAL [JP]) 6 September 2006 (2006-09-06) * paragraph [0005] * * page 8, line 40 - line 41 * * claim 14 *	3,6,7,9-11	A61K A61P
X	WO 2007/136116 A (TAISHO PHARMA CO LTD [JP]; KAKINUMA HIROYUKI [JP]; KOBASHI YOHEI [JP];) 29 November 2007 (2007-11-29) * the whole document *	1-11	
X	EP 1 731 524 A (KISSEI PHARMACEUTICAL [JP]) 13 December 2006 (2006-12-13) * claims 5-11 *	1-11	
		-/--	
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 11 October 2013	Examiner Albayrak, Timur
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

 1
EPO FORM 1503 03.02 (P04C01)



EUROPEAN SEARCH REPORT

Application Number
EP 13 18 1659

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	WO 2007/025943 A (BOEHRINGER INGELHEIM INT [DE]; BOEHRINGER INGELHEIM PHARMA [DE]; ECKHA) 8 March 2007 (2007-03-08) * claim 13 * * page 30, line 29 - line 30 * -----	1-11	
X	EP 1 364 958 A (KISSEI PHARMACEUTICAL [JP]) 26 November 2003 (2003-11-26) * claims 7,8 * -----	1-11	
X	EP 1 845 095 A (TAISHO PHARMA CO LTD [JP]) 17 October 2007 (2007-10-17) * paragraph [0207] * -----	1-11	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (IPC)
Place of search Munich		Date of completion of the search 11 October 2013	Examiner Albayrak, Timur
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

1
EPO FORM 1503 03 82 (P04001)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 13 18 1659

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

11-10-2013

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2008055940 A2	15-05-2008	AR 063627 A1	04-02-2009
		AU 2007316613 A1	15-05-2008
		CA 2669043 A1	15-05-2008
		CL 32272007 A1	04-07-2008
		CN 101534815 A	16-09-2009
		CO 6190509 A2	19-08-2010
		EA 200900626 A1	30-12-2009
		EP 2081569 A2	29-07-2009
		JP 2010509283 A	25-03-2010
		KR 20090089387 A	21-08-2009
		MA 30875 B1	02-11-2009
		NZ 598778 A	27-09-2013
		TW 200826946 A	01-07-2008
		US 2010298243 A1	25-11-2010
		WO 2008055940 A2	15-05-2008
		ZA 200902084 A	28-07-2010
WO 2008116179 A1	25-09-2008	AR 065809 A1	01-07-2009
		AU 2008228714 A1	25-09-2008
		CA 2681526 A1	25-09-2008
		CN 101686988 A	31-03-2010
		CN 102743340 A	24-10-2012
		EA 200901277 A1	26-02-2010
		EP 2139494 A1	06-01-2010
		EP 2508188 A1	10-10-2012
		JP 2010522244 A	01-07-2010
		KR 20090123964 A	02-12-2009
		PE 01852009 A1	28-02-2009
		TW 200904405 A	01-02-2009
		US 2008234366 A1	25-09-2008
		US 2011064801 A1	17-03-2011
		US 2012263786 A1	18-10-2012
		US 2013129819 A1	23-05-2013
		WO 2008116179 A1	25-09-2008
WO 2009143021 A1	26-11-2009	US 2011077213 A1	31-03-2011
		WO 2009143021 A1	26-11-2009
WO 2007093610 A	23-08-2007	AR 059489 A1	09-04-2008
		AT 517099 T	15-08-2011
		AU 2007216452 A1	23-08-2007
		BR PI0707849 A2	10-05-2011
		CA 2635838 A1	23-08-2007
		EA 200801773 A1	27-02-2009
		EC SP088605 A	29-08-2008
		EP 1989191 A1	12-11-2008

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 13 18 1659

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

11-10-2013

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
		JP 2009531291 A	03-09-2009	
		KR 20080102395 A	25-11-2008	
		TW 200801029 A	01-01-2008	
		US 2008058379 A1	06-03-2008	
		WO 2007093610 A1	23-08-2007	

EP 1698635	A1	06-09-2006	AT 537181 T	15-12-2011
			CA 2550441 A1	14-07-2005
			EP 1698635 A1	06-09-2006
			ES 2377937 T3	03-04-2012
			JP 4914611 B2	11-04-2012
			US 2008038242 A1	14-02-2008
			WO 2005063788 A1	14-07-2005

WO 2007136116	A	29-11-2007	AR 061026 A1	30-07-2008
			AU 2007252432 A1	29-11-2007
			BR PI0711949 A2	17-01-2012
			CA 2652707 A1	29-11-2007
			CN 101490028 A	22-07-2009
			EP 2076503 A2	08-07-2009
			JP 5067644 B2	07-11-2012
			JP 2009537509 A	29-10-2009
			KR 20090016456 A	13-02-2009
			NZ 573687 A	29-10-2010
			RU 2008150383 A	27-06-2010
			TW 200812995 A	16-03-2008
			US 2010022460 A1	28-01-2010
			WO 2007136116 A2	29-11-2007

EP 1731524	A	13-12-2006	CA 2560005 A1	13-10-2005
			EP 1731524 A1	13-12-2006
			US 2007185197 A1	09-08-2007
			WO 2005095429 A1	13-10-2005

WO 2007025943	A	08-03-2007	AR 056047 A1	12-09-2007
			AT 484499 T	15-10-2010
			CA 2620566 A1	08-03-2007
			JP 5175191 B2	03-04-2013
			JP 2009506094 A	12-02-2009
			TW 200800933 A	01-01-2008
			US 2007049537 A1	01-03-2007
			WO 2007025943 A2	08-03-2007

EP 1364958	A	26-11-2003	CA 2438595 A1	06-09-2002
			EP 1364958 A1	26-11-2003
			ES 2350084 T3	18-01-2011

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 13 18 1659

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

11-10-2013

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
		JP 4147111 B2	10-09-2008	
		TW 1249535 B	21-02-2006	
		US 2004116357 A1	17-06-2004	
		WO 02068440 A1	06-09-2002	

EP 1845095	A	17-10-2007	AT 523504 T	15-09-2011
			AU 2006204258 A1	13-07-2006
			BR PI0606397 A	11-03-2008
			CA 2592995 A1	13-07-2006
			CN 101103013 A	09-01-2008
			DK 1845095 T3	21-11-2011
			EP 1845095 A1	17-10-2007
			ES 2369030 T3	24-11-2011
			HK 1112239 A1	16-11-2012
			HR P20110791 T1	30-11-2011
			JP 4492968 B2	30-06-2010
			JP 5187592 B2	24-04-2013
			JP 2010059173 A	18-03-2010
			KR 20070098811 A	05-10-2007
			NZ 556342 A	30-04-2010
			PL 1845095 T3	29-02-2012
			PT 1845095 E	03-10-2011
			RS 52066 B	30-06-2012
			SI 1845095 T1	30-12-2011
			TW 1374882 B	21-10-2012
			US 2008132563 A1	05-06-2008
			US 2011098469 A1	28-04-2011
			WO 2006073197 A1	13-07-2006
			ZA 200706021 A	31-12-2008

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 6774112 B [0039] [0040] [0109]
- US 6515117 B [0040] [0045]
- US 6414126 B [0040] [0045]
- US 233617 A [0040]
- US 20060063722 A1 [0040]
- US 20050209166 A [0040]
- US 20060074031 A [0040]
- US 20060035841 A [0040]
- US 20060009400 A [0040]
- US 20060025349 A [0040]
- US 20060122126 A [0040]
- US 20060019948 A [0040]
- US 20060194809 A [0041]
- WO 0301180 A [0041]
- US 6908905 B [0041]
- US 6815428 B [0041]
- US 6555519 B [0041]
- US 6683056 B [0041]
- EP 598359 A1 [0042]
- EP 0850948 A1 [0042]
- JP 09188625 A [0042]
- JP 09124685 A [0042]
- JP 09124684 B [0042]
- EP 773226 A1 [0042]
- JP 08027006 A [0042]
- EP 684254 A1 [0042]
- JP 10245391 B [0043]
- US 20050233982 A [0044]
- US 20050119192 A [0044]
- WO 2006035796 A [0044]
- JP 2006117651 A [0044]
- JP 20044359630 B [0044]
- WO 2006080421 A [0044]
- US 20050233988 A [0044]
- WO 2005012321 A [0044]
- US 7015201 B [0044]
- WO 2006058597 A [0044]
- WO 2006011469 A [0044]
- US 20030195235 A [0044]
- WO 2006037537 A [0044]
- US 765481 A [0048]
- US 20080004336 A [0048]

Non-patent literature cited in the description

- **HEINIG et al.** *Cleveland Clinic Journal of Medicine*, 2006, vol. 73, 1059-1064 [0004]
- **K. TSUJIHARA et al.** *Chem. Pharm. Bull.*, 1996, vol. 44, 1174-1180 [0043]
- **M. HONGU et al.** *Chem. Pharm. Bull.*, 1998, vol. 46, 22-33 [0043]
- **M. HONGU et al.** *Chem. Pharm. Bull.*, 1998, vol. 46, 1545-1555 [0043]
- **A. OKU et al.** *Diabetes*, 1999, vol. 48, 1794-1800 [0043]
- **RYAN et al.** HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney. *Kidney International*, 1994, vol. 45, 48-57 [0078]